Capricor Therapeutics (NASDAQ:CAPR) Posts Quarterly Earnings Results, Beats Expectations By $0.15 EPS

Capricor Therapeutics (NASDAQ:CAPR) issued its quarterly earnings data on Wednesday. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.15, Zacks reports. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The company had revenue of $11.13 million during the quarter, compared to analyst estimates of $9.87 million.

Capricor Therapeutics Trading Up 17.5 %

Shares of NASDAQ:CAPR opened at $14.36 on Friday. The firm has a market cap of $652.95 million, a PE ratio of -13.55 and a beta of 4.10. The company has a fifty day simple moving average of $14.06 and a 200 day simple moving average of $14.50. Capricor Therapeutics has a 12-month low of $3.52 and a 12-month high of $23.40.

Analyst Upgrades and Downgrades

Several equities analysts have commented on CAPR shares. HC Wainwright reissued a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research report on Monday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $30.00 target price on shares of Capricor Therapeutics in a research note on Thursday. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $34.50.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.